Article Information
History
- April 13, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Craig Fenwick‡,1,
- Priscilla Turelli‡,2,
- Céline Pellaton1,
- Alex Farina1,
- Jérémy Campos1,
- Charlène Raclot2,
- Florence Pojer2,
- Valeria Cagno3,4,
- Giuseppe Pantaleo1,5,* and
- Didier Trono2,*
- 1Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 2School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- 3Department of Microbiology and Molecular Medicine, University of Geneva, Switzerland
- 4Institute of Microbiology, Lausanne University Hospital, University of Lausanne, Switzerland
- 5Swiss Vaccine Research Institute, Lausanne University Hospital and University of Lausanne, Switzerland
- ↵*Corresponding authors: Prof. Didier Trono, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, didier.trono{at}epfl.ch, Prof. Giuseppe Pantaleo, Service of Immunology and Allergy, Lausanne University Hospital, 1011 Lausanne, Switzerland, giuseppe.pantaleo{at}chuv.ch
↵‡ Authors contributing equally
Posted April 13, 2021.
A multiplexed high-throughput neutralization assay reveals a lack of activity against multiple variants after SARS-CoV-2 infection
